skip to main content

NOGG Below Threshold — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardMetabolic Bone DiseaseNOGG Below ThresholdSCE Rheumatology

A patient with active psoriatic arthritis and moderate-to-severe plaque psoriasis starts bimekizumab. At week 16 the skin is clear, but joint control is not maintained. Which labelled dosing pathway is available?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — After psoriasis loading, switch to 160 mg every 4 weeks if joint control fails

Explanation lettering: E = shown as A · C = shown as B · A = shown as C · B = shown as E

E is correct. Coexistent moderate-to-severe psoriasis uses 320 mg at weeks 0, 4, 8, 12 and 16, then every eight weeks. After week 16, if adequate joint response cannot be maintained, the SmPC allows consideration of a switch to 160 mg every four weeks. The decision is not a simple doubling or shortening of the psoriasis dose and illustrates phenotype-specific dosing.

Reference: Bimzelx 320 mg pre-filled pen SmPC: https://www.medicines.org.uk/emc/product/100224/smpc